Loading clinical trials...
Loading clinical trials...
A Phase I, Multi-centre, Open-label, Dose Exploration Study to Assess the Safety and Tolerability of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
Conditions
Interventions
Ceralasertib
Durvalumab
Locations
2
China
Research Site
Beijing, China
Research Site
Shandong, China
Start Date
September 23, 2022
Primary Completion Date
October 20, 2023
Completion Date
March 31, 2026
Last Updated
March 9, 2026
NCT06815575
NCT05508334
NCT04564027
NCT04907851
NCT03518606
NCT04434482
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions